Affinity Asset Advisors, LLC Zymeworks Inc. Transaction History

Affinity Asset Advisors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$15.19 - $29.33 $589,584 - $1.14 Million	-38,814 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$27.35 - $37.28 $241,062 - $328,585	8,814 Added 29.38%	38,814 $1.13 Million
Q2 2021 Aug 13, 2021	SELL	$26.5 - $38.23 $1.33 Million - $1.91 Million	-50,000 Reduced 62.5%	30,000 $1.04 Million
Q1 2021 May 14, 2021	BUY	$29.83 - $56.81 $447,450 - $852,150	15,000 Added 23.08%	80,000 $2.53 Million
Q4 2020 Feb 12, 2021	BUY	$39.12 - $54.99 $2.54 Million - $3.57 Million	65,000 New	65,000 $3.07 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $881M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.